SG11201908056QA - Anti-par2 antibodies and uses thereof - Google Patents
Anti-par2 antibodies and uses thereofInfo
- Publication number
- SG11201908056QA SG11201908056QA SG11201908056QA SG11201908056QA SG11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA
- Authority
- SG
- Singapore
- Prior art keywords
- building
- cambridge
- milstein
- international
- granta park
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 abstract 2
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 abstract 2
- 101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 abstract 2
- 102100036863 Solute carrier family 52, riboflavin transporter, member 1 Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472462P | 2017-03-16 | 2017-03-16 | |
| US201862637766P | 2018-03-02 | 2018-03-02 | |
| PCT/EP2018/056776 WO2018167322A1 (en) | 2017-03-16 | 2018-03-16 | Anti-par2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908056QA true SG11201908056QA (en) | 2019-09-27 |
Family
ID=61827709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908056QA SG11201908056QA (en) | 2017-03-16 | 2018-03-16 | Anti-par2 antibodies and uses thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10836822B2 (zh) |
| EP (1) | EP3596125A1 (zh) |
| JP (2) | JP7222901B2 (zh) |
| KR (1) | KR20190129925A (zh) |
| CN (1) | CN110446720B (zh) |
| AU (2) | AU2018235031B2 (zh) |
| BR (1) | BR112019018752A2 (zh) |
| CA (1) | CA3055251A1 (zh) |
| CL (1) | CL2019002626A1 (zh) |
| CO (1) | CO2019010975A2 (zh) |
| CR (1) | CR20190417A (zh) |
| IL (1) | IL269134B2 (zh) |
| MA (1) | MA49886A (zh) |
| MX (1) | MX2019010802A (zh) |
| NZ (1) | NZ757915A (zh) |
| PH (1) | PH12019502087A1 (zh) |
| SG (1) | SG11201908056QA (zh) |
| TW (1) | TWI788332B (zh) |
| UA (1) | UA125757C2 (zh) |
| WO (1) | WO2018167322A1 (zh) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2563483T3 (es) | 2008-04-11 | 2016-03-15 | Chugai Seiyaku Kabushiki Kaisha | Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno |
| US20140234340A1 (en) | 2010-11-30 | 2014-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| SG11201700841QA (en) | 2014-12-19 | 2017-03-30 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| KR20230044338A (ko) | 2014-12-19 | 2023-04-03 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 그의 사용 방법 |
| CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
| EP3574010A4 (en) | 2017-01-30 | 2020-12-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE |
| JP2023538379A (ja) | 2020-08-18 | 2023-09-07 | セファロン エルエルシー | 抗ｐａｒ－２抗体及びそれらの使用方法 |
| GB202204159D0 (en) | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US20070053911A1 (en) * | 2003-03-11 | 2007-03-08 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| JP2008519039A (ja) * | 2004-11-04 | 2008-06-05 | ニュー イングランド メデカル センター ホスピタルズ インク | Ｇタンパク質共役型受容体アゴニストおよびアンタゴニストならびに使用方法 |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| AR070911A1 (es) | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| ES2563483T3 (es) | 2008-04-11 | 2016-03-15 | Chugai Seiyaku Kabushiki Kaisha | Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno |
| ES2487846T3 (es) | 2008-05-01 | 2014-08-25 | Amgen, Inc. | Anticuerpos anti-hepcindina y métodos de uso |
| CA2733041A1 (en) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Effectors of par-2 activation and their use in the modulation of inflammation |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| SG183867A1 (en) | 2010-03-11 | 2012-10-30 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| WO2014022540A1 (en) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
| US9540449B2 (en) * | 2012-08-13 | 2017-01-10 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
| EP3160996B1 (en) * | 2014-06-30 | 2022-06-08 | Merck Patent GmbH | Anti-tnfa antibodies with ph-dependent antigen binding |
-
2018
- 2018-03-16 NZ NZ757915A patent/NZ757915A/en unknown
- 2018-03-16 CR CR20190417A patent/CR20190417A/es unknown
- 2018-03-16 IL IL269134A patent/IL269134B2/en unknown
- 2018-03-16 TW TW107109179A patent/TWI788332B/zh active
- 2018-03-16 EP EP18714185.8A patent/EP3596125A1/en active Pending
- 2018-03-16 JP JP2019549512A patent/JP7222901B2/ja active Active
- 2018-03-16 CN CN201880018128.7A patent/CN110446720B/zh active Active
- 2018-03-16 BR BR112019018752A patent/BR112019018752A2/pt unknown
- 2018-03-16 MX MX2019010802A patent/MX2019010802A/es unknown
- 2018-03-16 UA UAA201910275A patent/UA125757C2/uk unknown
- 2018-03-16 SG SG11201908056QA patent/SG11201908056QA/en unknown
- 2018-03-16 MA MA049886A patent/MA49886A/fr unknown
- 2018-03-16 US US15/923,374 patent/US10836822B2/en active Active
- 2018-03-16 WO PCT/EP2018/056776 patent/WO2018167322A1/en unknown
- 2018-03-16 AU AU2018235031A patent/AU2018235031B2/en active Active
- 2018-03-16 KR KR1020197030092A patent/KR20190129925A/ko not_active Application Discontinuation
- 2018-03-16 CA CA3055251A patent/CA3055251A1/en active Pending
-
2019
- 2019-09-13 PH PH12019502087A patent/PH12019502087A1/en unknown
- 2019-09-13 CL CL2019002626A patent/CL2019002626A1/es unknown
- 2019-10-03 CO CONC2019/0010975A patent/CO2019010975A2/es unknown
-
2020
- 2020-09-29 US US17/035,956 patent/US11591389B2/en active Active
-
2021
- 2021-10-27 AU AU2021257983A patent/AU2021257983A1/en active Pending
-
2023
- 2023-02-03 JP JP2023015469A patent/JP2023055895A/ja active Pending
- 2023-02-07 US US18/165,614 patent/US20230242639A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019502087A1 (en) | 2020-03-09 |
| JP7222901B2 (ja) | 2023-02-15 |
| CN110446720A (zh) | 2019-11-12 |
| CL2019002626A1 (es) | 2019-12-06 |
| KR20190129925A (ko) | 2019-11-20 |
| US10836822B2 (en) | 2020-11-17 |
| US20210061905A1 (en) | 2021-03-04 |
| US11591389B2 (en) | 2023-02-28 |
| JP2023055895A (ja) | 2023-04-18 |
| IL269134A (en) | 2019-11-28 |
| IL269134B1 (en) | 2024-03-01 |
| JP2020509762A (ja) | 2020-04-02 |
| US20180305450A1 (en) | 2018-10-25 |
| US20230242639A1 (en) | 2023-08-03 |
| CO2019010975A2 (es) | 2019-10-21 |
| IL269134B2 (en) | 2024-07-01 |
| EP3596125A1 (en) | 2020-01-22 |
| CR20190417A (es) | 2019-12-06 |
| AU2018235031B2 (en) | 2021-08-12 |
| WO2018167322A1 (en) | 2018-09-20 |
| TWI788332B (zh) | 2023-01-01 |
| BR112019018752A2 (pt) | 2020-05-05 |
| TW201843176A (zh) | 2018-12-16 |
| AU2021257983A1 (en) | 2021-11-25 |
| MA49886A (fr) | 2020-06-24 |
| AU2018235031A1 (en) | 2019-10-31 |
| CA3055251A1 (en) | 2018-09-20 |
| UA125757C2 (uk) | 2022-06-01 |
| NZ757915A (en) | 2023-05-26 |
| CN110446720B (zh) | 2023-09-12 |
| MX2019010802A (es) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201901172QA (en) | A method for manufacturing a fuel component | |
| SG11201910195WA (en) | Methods for trapping and barcoding discrete biological units in hydrogel |